Bone marrow disorder

This study looks at how well the drug asciminib works and how safe it is for young adults with chronic myeloid leukemia (CML) in the Gulf region. Researchers will collect information from medical records of about 80 people aged 18 and older who have taken asciminib. The main goal…

This phase I trial is testing whether combining three drugs—pacritinib, venetoclax, and azacitidine—is safe and tolerable for people with accelerated or blast phase myeloproliferative neoplasms, aggressive blood cancers. The study enrolls about 20 adults whose disease has progres…

This study tests whether adding a Chinese herbal formula (Xuanyin Ning) to a standard cancer drug (bevacizumab) can better control malignant pleural effusion—fluid buildup in the chest caused by advanced lung cancer. About 308 participants will receive either the herbal formula o…

This study tests whether adding the drug vorinostat to standard care can prevent graft-versus-host disease (GVHD) in children and young adults (ages 1-26) with non-cancerous blood disorders who are getting a bone marrow transplant. GVHD is a serious complication where donor cells…

This early-phase trial is testing an experimental therapy called GT737 for adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatment. GT737 uses specially engineered immune cells (iNKT cells) that are made in large batches and can be given…

This trial investigates whether adding bortezomib and sitagliptin to standard post-transplant cyclophosphamide can prevent graft-versus-host disease (GvHD) in adults with blood cancers receiving a stem cell transplant. Participants receive the drug combination after transplant, w…

This study tests a new combination of three drugs—revumenib, azacitidine, and venetoclax—in people newly diagnosed with a specific, hard-to-treat leukemia called KMT2A-rearranged AML. The goal is to see if this cocktail can help more patients achieve remission with fewer side eff…

This study tests whether taking a daily antibiotic (levofloxacin) can safely reduce infections in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) who are receiving chemotherapy as outpatients. The trial will randomly assign 75 participants to either lev…

This study tests whether giving personalized maintenance therapy after a stem cell transplant can prevent cancer from coming back in people with certain blood cancers. About 450 adults with myeloid cancers who have signs of disease before transplant will be assigned to treatment …

This study compares a new drug combination (venetoclax plus azacitidine) against standard chemotherapy for adults with a specific type of acute myeloid leukemia (AML) that has NPM1 or IDH mutations. About 148 people will be randomly assigned to one of the two treatments. The main…

This study tests a new oral drug called revumenib in people with acute myeloid leukemia (AML) who have certain genetic changes. After a stem cell transplant, participants will take revumenib or a placebo to see if it helps keep the cancer from coming back. The trial involves 144 …

This study tests whether removing a specific type of immune cell (naive T cells) from a donor's stem cell graft can prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the recipient's body. The trial enrolls people with non-malignant blood di…

This study tests a new combination of drugs (chidamide, venetoclax, azacitidine, and homoharringtonine) as a first treatment for adults aged 18-60 with intermediate- to high-risk acute myeloid leukemia (AML). The goal is to see if this mix can improve remission rates and reduce t…

This early-phase trial tests whether giving healthy stem cells from the mother to a fetus diagnosed with Fanconi anemia can safely improve the baby's blood cell production. The treatment is a one-time injection into the fetus during pregnancy. The study will enroll 12 pregnant wo…

This phase 2 trial tests whether adding olutasidenib to standard treatments helps people with IDH1-mutated acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). For AML, the standard is a chemotherapy pill plus venetoclax; for higher-risk MDS, it's the chemotherapy pill…

This trial tests rusfertide, an injected drug, in Japanese adults with polycythemia vera, a rare blood cancer that causes too many red blood cells. The goal is to see if rusfertide can keep red blood cell levels under control and reduce the need for phlebotomy (blood removal). Al…

This study looks at whether giving the drug venetoclax for a shorter time, along with the combination drug ASTX727, works as well as the usual longer course for adults aged 60 and older with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for strong chemot…

This study tests whether combining dasatinib with ropeginterferon can better control chronic myeloid leukemia in its early phase. About 40 adults newly diagnosed with CML will receive the drug pair to see if it improves disease control and reduces side effects. The goal is to man…

This pilot study tests whether the drug ropeginterferon is safe and feasible for 12 people with a JAK2 mutation and high-risk features who do not yet have a blood cancer. Participants receive an injection every 4 weeks and are monitored closely. The goal is to see if this approac…

This trial is testing a combination of three chemotherapy drugs—clofarabine, busulfan, and melphalan—given before a stem cell transplant in 30 adults with acute myeloid leukemia (AML) who are in first remission. The goal is to see if this conditioning regimen improves survival an…

This study tests whether a two-week course of the VA-CAG chemotherapy works as well as the usual three-week course for adults newly diagnosed with acute myeloid leukemia (AML). About 110 participants will be randomly assigned to one of the two schedules. The goal is to see if the…

This study looks at whether a higher dose of the blood thinner clopidogrel works better for people with essential thrombocythemia (ET), a rare blood disorder that raises the risk of dangerous blood clots. The standard dose may not work well for many ET patients, so researchers wi…

This study tests a new two-drug combination (pacritinib plus azacitidine) for people with moderate to very high risk myelodysplastic syndrome (MDS), a bone marrow disorder. The first part finds the safest dose of pacritinib, and the second part checks how well the combination wor…

This study will follow about 98 adults with chronic myeloid leukemia who are taking asciminib after other treatments have stopped working. Researchers want to see how many patients achieve a major molecular response (a key sign of disease control) after two years. The goal is to …

This phase I trial tests a new treatment for adults with acute myeloid leukemia (AML) who have minimal residual disease (MRD) — small amounts of cancer cells that remain after standard therapy. The treatment uses the patient's own T cells, genetically modified to recognize a prot…

This phase 2 trial tests whether adding two drugs (SHR2554 and azacitidine) to standard chemotherapy before a stem cell transplant can help people with high-risk or relapsed/refractory acute leukemia or myelodysplastic syndromes. About 180 participants aged 15-60 will be randomly…

This trial tests a new automated radiation method that precisely targets bone marrow and lymph nodes before a stem cell transplant. The goal is to kill cancer cells while reducing damage to healthy tissues. Participants have high-risk myeloid cancers like acute myeloid leukemia o…

This study tests whether adding a new drug called revumenib to the usual treatment (blinatumomab plus chemotherapy) can better clear leftover leukemia cells in people with a specific genetic type of B-cell acute lymphoblastic leukemia (ALL) or mixed-lineage leukemia. About 90 adu…

This trial investigates whether adding selinisole to standard chemotherapy drugs (azacitidine and venetoclax) can improve outcomes for people with newly diagnosed, high-risk myeloid tumors that have a TP53 mutation. These tumors are aggressive and hard to treat. The study will me…

This study is testing whether a two-drug combination (venetoclax and azacitidine) followed by a stem cell transplant can help people with a rare, hard-to-treat form of acute myeloid leukemia (AML). The trial will enroll 50 adults who have not been treated before. The goal is to s…

This study tests a new drug, INCA033989, against the best current treatments for people with a rare blood cancer called essential thrombocythemia who have a specific gene mutation (CALR). About 426 adults who have already tried at least one prior therapy will be randomly assigned…

This study tests a combination of seven drugs (including asciminib and venetoclax) in 30 adults with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute myeloid leukemia. The first phase checks safety, and the second phase sees if the combo helps control t…

This study tests a pill called selinexor in 15 adults with chronic blood cancers (MPN) whose blood cell counts are too high. The goal is to see if selinexor can safely bring those counts down and ease symptoms. Participants take the drug once a week for up to 3 months and are fol…

This early-phase study tests a new drug (ATRN-119) combined with a standard chemotherapy (decitabine) in 27 adults with acute myeloid leukemia or high-risk myelodysplastic syndrome that has a TP53 gene change. The main goals are to find a safe dose and see if the combo can shrink…

This study tests whether adding the experimental drug IPN60340 to standard medicines (azacitidine and venetoclax) helps more people with newly diagnosed acute myeloid leukemia (AML) achieve complete remission. About 450 adults who cannot have intensive chemotherapy will take part…

This Phase 3 trial tests whether elritercept can improve anemia in people with myelofibrosis who are already taking ruxolitinib. About 324 participants will receive either elritercept or a placebo for at least 9 months. The main goal is to see if the drug reduces the need for red…

This early-stage study tests a new tablet, FXS0683, in 228 adults with blood cancers like lymphoma or leukemia that returned or didn't respond to standard therapy. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will be clo…

This study tests a reduced-intensity chemotherapy combination (fludarabine and treosulfan) before a half-matched stem cell transplant in 77 older or frail adults with AML. The goal is to see if this gentler regimen can control the leukemia long-term while being safe enough for pa…

This early-phase study tests a new drug called PLM-102 in 12 adults whose acute myeloid leukemia (AML) has come back or not responded to standard treatments. The main goals are to find the highest safe dose and to monitor side effects. Participants must have relapsed or refractor…

This study tests if lisinopril, a common blood pressure drug, can lower red blood cell levels in people with polycythemia (too many red blood cells). Researchers will measure changes in hemoglobin, hematocrit, and a hormone called erythropoietin. The trial enrolls 30 adults with …

This early-stage trial tests a new treatment called QUAIL-100, made from a live weakened bacteria, in children and young adults with high-risk leukemia or myelodysplastic syndrome who have already had a stem cell transplant. The main goal is to check safety and side effects. Only…

This phase II trial tests whether adding venetoclax to standard chemotherapy and stem cell transplant, followed by venetoclax maintenance, helps adults with acute myeloid leukemia (AML) stay in remission longer. About 244 participants will receive either venetoclax or a placebo a…

This early-phase trial is testing a new personalized therapy called BSB-2002 for adults with a specific type of acute myeloid leukemia (AML) that has come back or not responded to treatment. The therapy uses a patient's own immune cells (T cells) that are genetically modified to …

This early-phase trial tests two oral drugs, olutasidenib and ziftomenib, together in 20 adults with a specific form of acute myeloid leukemia (AML) that has returned or not responded to treatment. The first part finds a safe dose; the second checks if that dose helps control the…

This trial looks at whether children with cancer who develop a fever and low white blood cells can safely stop antibiotics earlier than usual. About 136 children will be randomly assigned to either stop antibiotics within 24 hours or continue standard treatment. The goal is to se…

This study tests a targeted radiation technique (TMLI) combined with two chemotherapy drugs before a stem cell transplant in people aged 50 and older with acute myeloid leukemia or myelodysplastic syndrome that has not responded to treatment or has returned. The goal is to see if…

This study tests whether adding pivekimab sunirine to the standard drugs venetoclax and azacitidine helps adults with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for intensive chemotherapy. About 660 participants will be randomly assigned to receive ei…

This study looks at a stem cell transplant from a half-matched donor (haploidentical) combined with drugs to prevent the cancer from coming back. It includes 40 adults aged 18-65 with active AML that has returned or not responded to treatment. The goal is to see if this approach …

This study tests a combination of two drugs (Bcl-2 inhibitor and azacitidine) in people newly diagnosed with a rare and aggressive leukemia called mixed phenotype acute leukemia (MPAL). About 52 participants will receive the treatment, with an extra drug added for a specific subt…

This phase 2 trial tests ropeginterferon alfa-2b, a long-acting immune protein, in 35 adults with rare blood cancers like CMML and MDS/MPN overlap syndromes. The drug aims to slow cancer cell growth by boosting the immune system. Researchers will check safety, best dose, and how …

This study tests whether a combination of three chemotherapy drugs (thiotepa, busulfan, and fludarabine) given before a stem cell transplant can help older adults with acute myeloid leukemia stay in remission longer. About 93 patients aged 55 to 75 who are in their first remissio…

This Phase 2 trial tests a combination of two drugs—blinatumomab (given as a shot under the skin) and olverembatinib (a pill)—in 60 adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). The goal is to see if this combo can control the disease safely. Pa…

This study tests whether adding SHR2554 and azacitidine to standard chemotherapy before a stem cell transplant can lower the chance of cancer returning in people aged 15-60 with high-risk or relapsed leukemia or myelodysplastic syndromes. Half the participants will get the new dr…

This study tests a stem cell transplant from a matched sibling donor combined with special immune cells (regulatory and conventional T cells) for people with high-risk acute myeloid leukemia (AML). The goal is to prevent the cancer from coming back. About 28 participants will rec…

This Phase 2 trial tests the drug imetelstat in 30 adults with myelodysplastic/myeloproliferative neoplasms (MDS/MPN), a rare blood cancer. The goal is to see if imetelstat can help control the disease and to check for side effects. Participants receive the drug by IV, and the st…

This study tests an experimental drug, TQ05105, in 51 adults with intermediate or high-risk myelofibrosis, a serious bone marrow disease. The drug is for patients whose previous treatment (JAK inhibitors) stopped working or caused side effects. The main goal is to see if the drug…

This early-phase study tests a new type of CAR-T cell therapy (FO33 CAR-T) for people with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target a protein called CD33 found on mos…

This early-phase study tests whether giving two drugs—ruxolitinib and azacitidine—after a stem cell transplant can safely prevent graft-versus-host disease (GVHD) and keep acute myeloid leukemia (AML) from coming back. About 40 adults with AML in remission will receive ruxolitini…

This phase 2 trial tests asciminib, a newer targeted drug, alone or with dasatinib, in 45 adults with chronic myeloid leukemia (CML) whose first treatment stopped working. The goal is to see if this approach can reduce cancer cells to very low levels within 24 weeks. Patients wit…

This study tests whether the drug luspatercept can prevent severe anemia (low red blood cells) after a stem cell transplant in people with blood cancers and a bone marrow condition called myelofibrosis. About 196 adults will receive either luspatercept or standard supportive care…

This Phase 3 trial tests whether adding venetoclax to azacitidine as maintenance therapy helps adults with acute myeloid leukemia (AML) stay in remission longer. About 788 patients who achieved first remission after initial treatment will receive either azacitidine alone or azaci…

This study tests whether patients can safely stop the drug tacrolimus earlier than usual after a stem cell transplant. Tacrolimus is given to prevent graft-versus-host disease (GVHD), but newer methods have lowered GVHD risk. The trial will enroll 50 people with blood cancers and…

This early-phase study tests whether adding the drug ropeginterferon alfa-2b to the standard treatment ruxolitinib is safe for people with myelofibrosis, a type of bone marrow cancer. About 15 adults already on a stable dose of ruxolitinib will receive the combination. The main g…

This early-phase study tests an experimental drug, ZE74-0282, in about 60 adults with polycythemia vera or myelofibrosis caused by a specific JAK2 gene mutation. The main goals are to find a safe dose and check for side effects, while also seeing if the drug shows signs of fighti…

This study tests a new oral liquid drug, BLEX 404, combined with a standard chemotherapy (azacitidine) for people with certain types of bone marrow cancers (MDS and CMML). The goal is to find a safe dose and see if it can reduce serious infections. About 52 adults who have not be…

This Phase 3 trial will test whether adding homoharringtonine to the standard two-drug regimen of venetoclax and azacitidine improves remission rates in adults aged 60-75 with newly diagnosed acute myeloid leukemia (AML). About 308 participants will be randomly assigned to receiv…

This Phase 2 trial tests whether adding other drugs to standard chemotherapy can eliminate leftover leukemia cells in adults aged 18-59 before a stem cell transplant. Participants who still have detectable disease after initial treatment will receive one of four drug combinations…

This study tests whether a combination of three drugs (chidamide, venetoclax, and azacitidine) can help prevent acute myeloid leukemia (AML) from coming back in patients who have already achieved remission. About 104 adults aged 18 to 80 will receive up to 12 cycles of treatment.…

This early-phase trial tests a new cell therapy called ThINKK in 12 children aged 2–12 who have had a stem cell transplant for leukemia or neuroblastoma. The therapy is designed to boost the body's natural killer (NK) cells to better fight cancer. The main goals are to check if t…

This study compares two FDA-approved drugs, momelotinib and ruxolitinib, in people with myelofibrosis who also have low blood cell counts. The main goal is to see which drug does a better job at shrinking the spleen and reducing the need for blood transfusions. About 268 particip…

This early-phase trial is testing a new drug called axatilimab added to two standard chemotherapy drugs (decitabine and venetoclax) for people with acute myeloid leukemia (AML) that has a TP53 mutation or deletion. The study aims to find the safest dose of axatilimab and see how …

This early-phase trial tests a new approach using donor immune cells that have been mobilized through exercise to prevent or treat leukemia relapse after a stem cell transplant. The study will enroll 94 people with various blood cancers. Some will receive the exercise-mobilized c…

This study tests whether taking two oral medications (decitabine and ivosidenib) together can control acute myeloid leukemia (AML) in patients aged 60+ or those too frail for standard chemo. About 50 participants will take the pills in 28-day cycles until the disease worsens or s…

This study tests a combination of three drugs (venetoclax, homoharringtonine, and azacitidine) plus a growth factor (G-CSF) in 61 older or frail adults with newly diagnosed acute myeloid leukemia (AML) who cannot tolerate standard intensive chemotherapy. The goal is to see if thi…

This phase 2 trial tests a new combination of drugs—lisafotoclax, decitabine, and homoharringtonine—in 35 adults with acute myeloid leukemia (AML) whose cancer did not respond to or could not tolerate the standard venetoclax/azacitidine regimen. The goal is to see if this new mix…

This study tests whether a three-drug combination (venetoclax, azacitidine, and gilteritinib) followed by strong chemotherapy works better than standard chemotherapy plus gilteritinib for adults with a specific genetic type of acute myeloid leukemia (FLT3-mutated AML). About 300 …

This study tests a new drug, TGRX-678, in adults with chronic-phase chronic myeloid leukemia (CML) whose cancer has stopped responding to or caused side effects from at least three prior treatments. Participants will receive either TGRX-678 or another standard drug chosen by thei…

This phase 2 trial tests whether adding asciminib to standard tyrosine kinase inhibitors can prevent relapse in patients with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia or blastic phase chronic myeloid leukemia after a stem cell transplant. 45 participan…

This Phase 3 trial tests a new combination of drugs (venetoclax, azacitidine, and a liposomal form of mitoxantrone) against the standard therapy for adults newly diagnosed with acute myeloid leukemia (AML). The study will enroll 204 people aged 18-65 to see if the new combo leads…

This study tests a combination of three drugs—aclarubicin, azacitidine, and venetoclax—in people with acute myeloid leukemia (AML) who are either newly diagnosed and unable to tolerate standard chemotherapy, or whose cancer has returned or not responded to treatment. The trial ha…

This study compares a single antibiotic (amoxicillin-clavulanate) against the standard two-drug combination (amoxicillin-clavulanate plus ciprofloxacin) for treating fever caused by chemotherapy in adults with certain blood cancers. The goal is to see if the simpler treatment wor…

This phase 3 trial will test whether adding the drug quizartinib to the standard two-drug combination (venetoclax and azacitidine) helps adults with newly diagnosed acute myeloid leukemia (AML) live longer. The study includes 376 people aged 18 and older who cannot receive intens…

This phase II trial tests two oral drugs, selinexor and pacritinib, in 26 adults with myelofibrosis who have anemia and low platelets and have not taken JAK inhibitors before. The main goal is to see if the combination can shrink the spleen by at least 35%. The study also tracks …

This study tests whether adding ivosidenib to oral azacitidine (Onureg) can help prevent acute myeloid leukemia (AML) from coming back in people over 55 who have a specific IDH1 mutation and are already in remission after chemotherapy. About 60 participants will take both pills d…

This study tests a drug called ziftomenib in 70 adults with acute myeloid leukemia (AML) who have specific gene changes (NPM1 or KMT2A) and cannot receive standard chemotherapy. Ziftomenib blocks a protein called menin that helps cancer cells grow. The goal is to see if the drug …

This study tests whether the drug gecacitinib, given before, during, and after a stem cell transplant, can help people with myelofibrosis (a type of bone marrow cancer) have better outcomes. About 39 adults aged 18-75 with intermediate- or high-risk myelofibrosis will take part. …

This trial tests a new way to do cord blood transplants for young adults (ages 16-55) with very poor risk acute myeloid leukemia (AML). Participants get a standard cord blood transplant plus daily infusions of white blood cells called granulocytes for 1 to 7 days. The goal is to …

This study tests an experimental drug called BL-M11D1 combined with either standard chemotherapy or another targeted therapy in 216 adults newly diagnosed with acute myeloid leukemia (AML). The goal is to see if the combination is safe and works better at controlling the cancer. …

This study tests whether the drug interferon-α can lower the chance of cancer returning in people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who have a TP53 gene mutation. Participants must have had a stem cell transplant and show no signs of cancer two m…

This study tests an oral chemotherapy drug, cladribine, combined with two other drugs (low-dose cytarabine and venetoclax) in people with acute myeloid leukemia (AML). The first part finds the safest dose; the second part checks if that dose helps control the disease. About 58 ad…

This early-stage study tests a new treatment using special immune cells (CAR-T cells) designed to reduce harmful antibodies that can prevent or damage bone marrow transplants. About 18 people with blood diseases who have these antibodies will receive the cells in increasing doses…

This early-phase study tests whether adding a new drug called eganelisib to two standard AML medications (venetoclax and azacitidine) is safe for people with acute myeloid leukemia that has come back or not responded to treatment. About 48 adults will take part to find the best d…

This early-stage study tests a new drug, CT1390B, in 18 adults whose acute myeloid leukemia has come back or not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink or clear the cancer. Participants must be bet…

This study tests a special way to process donated stem cells to make transplants safer for people with leukemia or lymphoma. The goal is to reduce serious complications like graft-versus-host disease, where donor cells attack the patient's body. About 100 participants will receiv…

This study tests whether adding a bone-strengthening drug (bisphosphonate) to a standard antibiotic (vancomycin) can better control chronic bone infections that are hard to treat. About 280 adults with a specific type of bone infection will be randomly assigned to get either the …

This study tests whether a new drug called gecacitinib, combined with standard anti-rejection medicine, can prevent a serious complication called graft-versus-host disease (GVHD) in people with myelofibrosis who receive a stem cell transplant. About 40 adults will take part. The …

This study tests a new three-drug combination (gilteritinib, azacitidine, and venetoclax) against standard chemotherapy for adults with a specific genetic subtype of acute myeloid leukemia (FLT3-ITD). About 230 newly diagnosed patients aged 18-75 who are healthy enough for intens…

This early-stage study tests a new type of CAR-T cell therapy for adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The therapy uses donor cells engineered to target a protein called CLL1 found on most AML cells, and is designed …

This study tests a combination of three drugs (cladribine, low dose cytarabine, and venetoclax) in 24 adults with acute myeloid leukemia (AML) that has relapsed or not responded to prior treatment, especially after a venetoclax-based regimen. The goal is to see if this combinatio…

This study tests whether adding bomedemstat to the standard drug momelotinib can help people with myelofibrosis, a type of bone marrow cancer. It is for patients whose spleen is still enlarged after 12 weeks on momelotinib alone. The main goal is to see if the combination reduces…

This early-phase trial tests adding tocilizumab, a drug used for arthritis, to standard chemotherapy (azacitidine and venetoclax) for adults with acute myeloid leukemia (AML) who cannot have intensive treatment. The main goal is to find a safe dose and check for side effects. Onl…

This study tests a combination of two newer drugs, blinatumomab and venetoclax, along with standard chemotherapy, for adults with a rare type of leukemia called acute leukemia of ambiguous lineage (ALAL). The goal is to see if this approach improves survival and remission rates. …

This study tests whether giving a shorter course of the drug venetoclax (combined with azacitidine) works as well as the standard longer course for older or frail patients with acute myeloid leukemia (AML). The researchers will check bone marrow on day 14 to decide if the drug ca…

This study tests a drug called ivarmacitinib to prevent acute graft-versus-host disease (aGVHD) in 32 people with blood cancers receiving a half-matched stem cell transplant. The goal is to see if the drug can lower the chance of severe GVHD and improve survival without long-term…

This early-phase study tests a new type of CAR-T cell therapy for adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to better find and attack leukemia cells. The main goal i…

This early-phase study tests two oral drugs, ziftomenib and mezigdomide, given together to adolescents and adults with acute myeloid leukemia (AML) that has come back or not responded to treatment. The trial focuses on people whose leukemia has specific genetic changes (KMT2A rea…

This early-phase study tests whether adding an experimental drug (VIC-1911) to standard medications can prevent graft-versus-host disease (GVHD) in children aged 8-18 who receive a stem cell transplant from a half-matched donor. GVHD occurs when donor cells attack the child's bod…

This study tests a two-step treatment for people with acute myeloid leukemia (AML) that has come back or not responded to standard chemo. First, patients receive CLL1 CAR-T cells (engineered immune cells that target leukemia). Then they get a stem cell transplant from a donor. Th…

This early study tests a new treatment using the body's own immune cells, called CAR-T cells, to fight certain blood cancers (like T-cell leukemia/lymphoma) that have returned or not responded to standard therapy. The study will enroll about 20 to 28 adults aged 18-85. The main g…

This early-phase trial tests a new type of cell therapy called CAR-ITNK cells, designed to target two proteins (CD70 and CLL1) on leukemia cells. It will enroll 30 adults with relapsed or refractory acute myeloid leukemia (AML) who have not responded to standard treatments. Parti…

This early-phase study tests a new treatment called CLL-1 CAR-T for children aged 3 to 18 with acute myeloid leukemia that has come back or not responded to standard therapy. Ten participants will receive an infusion of their own modified immune cells after chemotherapy. The main…

This study tests whether starting tube feeding right after a stem cell transplant can reduce severe gut graft-versus-host disease (GVHD) in people with blood cancers or disorders. About 112 participants will be randomly assigned to either standard care or early tube feeding. The …

This study compares two ways of giving donor immune cells (DLI) after a stem cell transplant to prevent cancer from coming back in people with relapsed or hard-to-treat acute myeloid leukemia or myelodysplastic syndromes. One approach gives the cells early as a preventive measure…

This phase 3 trial is testing whether an oral (pill) form of arsenic trioxide works as well as the standard IV form for consolidation therapy in people with a low-risk type of acute promyelocytic leukemia (APL). About 120 adults and teens who have already completed initial treatm…

This early-phase study tests a new drug called lonitoclax combined with azacitidine in 66 adults whose acute myeloid leukemia has returned or not responded to prior treatment. The main goal is to find a safe dose and check for early signs that the combination might help control t…

This early-phase study tests a new type of immune therapy for people with certain blood cancers (leukemias) that have returned or not responded to standard treatments. The therapy uses the patient's own T cells, which are modified in the lab to recognize and attack cancer cells c…

This study looks back at medical records of 150 people with polycythemia vera (a rare blood cancer) who received ropeginterferon alfa-2b. Researchers want to see how well the drug controls the disease over time and what factors help or hinder its effectiveness. The goal is to imp…

This study tests whether combining two oral drugs, sorafenib and venetoclax, can eliminate leftover leukemia cells in people with acute myeloid leukemia (AML) who still have measurable residual disease (MRD) after initial treatment. About 87 participants will receive the drugs fo…

This phase 2 trial tests a reduced-toxicity chemotherapy regimen (thiotepa, melphalan, fludarabine) before a stem cell transplant in 40 people with blast-phase chronic myeloid leukemia (CML), an advanced and hard-to-treat stage. The goal is to see if this gentler approach can imp…

This early-stage trial tests a new treatment called CT0991, which uses a patient's own immune cells engineered to attack leukemia cells. It will enroll 24 adults with acute myeloid leukemia that has returned or not responded to standard therapy. The main goals are to check safety…

This study tests a new drug combination using selinexor with fewer or no harsh chemo drugs for adults newly diagnosed with acute myeloid leukemia (AML) who are too frail for standard intensive chemo. The goal is to quickly reduce leukemia cells while causing fewer side effects. A…

This study tests a new treatment for acute myeloid leukemia (AML) that has returned or not responded to standard therapy. It uses specially modified immune cells from a healthy donor to attack the cancer. The first part finds the safest dose, and the second part checks how well i…

This phase 2 trial tests whether adding venetoclax to standard chemotherapy before a stem cell transplant can improve survival for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The study will enroll 27 adults aged 18 to 75. The main goal is…

This early-phase trial tests a two-step treatment for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. First, patients receive special immune cells (CAR-T cells) that target two markers on leukemia cells, followed by a second type …

This study tests whether infusing umbilical cord blood can safely help elderly patients (ages 60-80) with MDS or AML recover from bone marrow suppression caused by chemotherapy. The treatment aims to improve blood cell counts and reduce complications like bleeding and infection. …

This study offers continued RVU120 treatment to up to 10 patients with advanced solid tumors, acute myeloid leukemia, or high-risk myelodysplastic syndrome who are already benefiting from the drug in an earlier trial. The main goal is to monitor safety and see how long patients c…

This study tests a new treatment called CCTx-001 for adults with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. CCTx-001 is a type of immunotherapy that uses a patient's own immune cells, modified to target a protein called IL-1RAP found …

This study tests a new approach for people with relapsed or refractory acute myeloid leukemia (AML) who have active disease. Before a stem cell transplant, patients receive a radioactive antibody (131I-apamistamab) along with chemotherapy and low-dose radiation to prepare the bod…

This study tests two chemotherapy drugs, treosulfan and melphalan, given before a stem cell transplant in 220 adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to see which drug works better at helping patients survive longer with fewer side …

This study aims to develop a new blood test that could replace the invasive bone marrow biopsy currently used to diagnose myeloproliferative neoplasms (MPNs), a group of blood cancers. Researchers will collect blood samples from 500 adults with suspected or confirmed MPN and anal…

This study tests a new blood test (5hmC) to see if it can help doctors choose between two standard treatments for acute myeloid leukemia (AML): a milder drug (hypomethylating agent) or strong chemotherapy. About 112 newly diagnosed adults will have their blood tested after initia…

This study looks at 60 people with acute myeloid leukemia to see if a computer method (FlowSOM) can detect leftover cancer cells as well as expert analysis. Researchers will compare results from both methods using stored blood samples. If the computer approach works, it could mak…

People with Fanconi anaemia have a high risk of developing oral cancer, but standard biopsies are painful and risky due to their genetic sensitivity. This study tests a non-invasive oral brushing technique to detect early cancer cells in 115 patients aged 15 and older. If accurat…

This study will test whether a highly sensitive genetic test called digital PCR can detect drug-resistant mutations in people with chronic myeloid leukemia (CML) as well as the current standard method. Researchers will analyze blood samples from 150 adults with CML whose current …

This study tests whether the drug Lisaftoclax can prevent differentiation syndrome (DS), a severe and sometimes life-threatening side effect, in people with acute promyelocytic leukemia (APL) who are receiving standard treatment. About 60 participants aged 16 and older will take …

This study tests whether light therapy (photobiomodulation) can prevent mouth sores in children receiving chemotherapy. Fifty children aged 0-30 will receive daily light treatments during hospital stays and at home. Researchers will check if the therapy is easy to use and accepta…

This study will test different methods to prevent infections and other problems from central lines (tubes placed in large veins) in 2,500 patients. It compares special antimicrobial caps and a skin anchor device against standard care. The goal is to find the best ways to keep pat…

This study tests whether a new medicine called Fexuprazan (Fexuclue) can prevent stomach ulcers caused by NSAID painkillers like ibuprofen. About 360 adults with joint or muscle pain who need daily NSAIDs will take either Fexuprazan or an older drug (Lansoprazole) for 24 weeks. T…

This study compares two ways to break up kidney stones using a laser and a suction device. One method turns stones into dust, the other into small fragments. The goal is to see which leaves fewer stone pieces behind after one month. About 86 adults with small kidney stones will t…

This study tests whether the drug zoledronate can reduce pain in children aged 4 to 17 with chronic recurrent multifocal osteomyelitis (CRMO), a rare auto-inflammatory bone disease. The 30 participants have not responded to standard anti-inflammatory drugs. They will receive eith…

This study tests a new drug, JMKX000197, against a standard chemotherapy drug (cisplatin) to see which works better at controlling fluid buildup around the lungs in people with advanced cancer. About 120 participants with moderate to large fluid collections will receive the drug …

This study tests a home-based exercise program called CAREFit-BMT for people with high-risk acute myeloid leukemia who are about to have a stem cell transplant. The program includes aerobic and strength training to improve heart function before the procedure. Researchers will enr…

This study tests a special gel (HA35) applied to the jaw at night to relieve pain and muscle tightness from temporomandibular joint disorder (TMD). About 30 adults with TMD will use the gel nightly for 8-12 hours. Researchers will check how well it reduces pain and tension after …

This study tests an online music therapy program that combines mindfulness and music to help people recovering from stem cell transplants for blood cancers. Researchers want to see if it can improve quality of life, reduce pain, fatigue, anxiety, and depression, and possibly spee…

This study tests whether a 12-week personalized exercise program can reduce fatigue and improve physical function in people with myeloproliferative neoplasms (MPN) and chronic myeloid leukemia (CML). Participants will do supervised aerobic and resistance training twice a week plu…

This pilot study will test whether a non-invasive vagus nerve stimulation (nVNS) device can reduce jaw pain and improve mood in 10 premenopausal women with temporomandibular disorders (TMD). Participants will receive the treatment twice a week for 8 weeks and undergo brain scans,…

This early-phase trial will test four orthobiologic treatments—PRP, bone marrow concentrate, hyaluronic acid, and nanofat—in 300 adults with various muscle, joint, tendon, or bone conditions. The goal is to see if these natural substances can reduce pain and improve joint functio…

This study tests whether a 3-month personalized exercise program can improve quality of life, fitness, and symptoms in people with myeloproliferative neoplasms (MPN), a group of rare blood cancers. About 80 participants will be randomly assigned to either start the exercise progr…

This study compares hypnosis, virtual reality, and standard care to see which best reduces anxiety in adults starting chemotherapy for acute myeloid leukemia. About 99 patients will be randomly assigned to one of three groups. The goal is to find a non-drug way to help patients c…

This study looks at whether a mobile app can help people with common pains (neck, shoulder, back, or knee) do their prescribed home exercises more regularly. About 30 adults will be split into two groups: one using the app and one doing traditional exercises. The goal is to see i…

This study tests a digital app called WELL-MPN designed to help adults with myeloproliferative neoplasms (MPNs) improve their diet, physical activity, symptoms, and emotional well-being. About 75 participants will be randomly assigned to use the app or receive standard written li…

This study tests whether adding core-strengthening exercises to standard physical therapy can reduce pain and improve function in people with temporomandibular joint (TMJ) disorders. Fifty adults with jaw pain will be randomly assigned to either standard TMJ therapy or standard t…

This study screens up to 1,000 people with personal or family histories of certain cancers to see if they qualify for ongoing genetics research at the National Cancer Institute. Participants fill out a 15-20 minute online survey about their health and family history. No treatment…

This study will follow 200 children with acute lymphoblastic leukemia or lymphoma to learn more about the short- and long-term side effects of asparaginase drugs. Researchers will track how often serious toxicities occur during standard treatment and a newer therapy called SJALL2…

This study looks at whether screening adults with leukemia for social needs (like housing or food) and offering early social work help is practical and helpful. About 80 newly diagnosed patients will either get the screening and consultation or usual care. The goal is to see if t…

This study will collect blood and bone marrow samples from 55 adults with acute leukemia or myelodysplastic syndrome. Researchers want to understand how natural killer (NK) cells interact with cancer cells over time. The goal is to identify genetic markers and immune patterns tha…

This study looks at whether using a cousin as a stem cell donor works as well as using a sibling for people with blood cancers. Researchers will compare survival, relapse, and side effects like graft-versus-host disease in patients who received a transplant from either a cousin o…

This study will observe 10 adults with acute myeloid leukemia who are receiving the drug gilteritinib after a stem cell transplant. Researchers want to understand how gilteritinib affects the behavior, metabolism, and function of immune cells like T-cells and monocytes. The goal …

This study aims to create a score that uses a special blood test to predict bleeding risk in people with blood cancers and very low platelet counts. Researchers will take an extra blood sample from 410 participants and analyze it with viscoelastometric tests. The goal is to ident…

This study will look at whether SPECT scans taken after Lu-PSMA therapy can help predict how well patients with metastatic castration-resistant prostate cancer (mCRPC) are doing. Researchers will measure tumor activity and volume on the scans and compare them to standard PET-base…

This study aims to translate and adapt a widely used questionnaire for musculoskeletal problems into Urdu. Researchers will enroll 110 Urdu-speaking adults, including patients with muscle or joint issues and healthy volunteers. The goal is to create a validated tool to measure sy…

This early-stage study in 16 healthy adults checks if taking a common stomach acid drug (rabeprazole) changes how the body absorbs a new experimental drug (TQ05105) being developed for myelofibrosis. Participants take TQ05105 alone and later with rabeprazole to compare drug level…

This study is testing a new blood test called AlloHeme that looks for tiny traces of a patient's own cells after a stem cell transplant. The goal is to see if the test can predict whether leukemia or MDS will come back before it happens. About 400 adults who have had or will have…

This study looks at how patients feel when reading their own medical notes. Some will read the original doctor's note, others will read a simpler version written by artificial intelligence. Researchers want to see if the AI summary changes how much patients trust their doctor or …

This early-phase study at St. Jude Children's Research Hospital will test whether it is safe and possible to collect blood stem cells from 12 young adults with inherited bone marrow failure syndromes. Participants will receive two drugs (filgrastim and plerixafor) to move stem ce…

This study will review medical records of 400 adults in Kuwait with chronic myeloid leukemia (CML) who have received at least one type of targeted therapy (TKI). Researchers want to understand patient backgrounds, other health conditions, and how treatments are used in everyday p…

This study explores whether a non-invasive, painless skin measurement called electrical bioimpedance can help monitor acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). About 25 adults who are already scheduled for a bone marrow biopsy will also receive this skin te…

This study looks at a new method to measure special immune cells called iNKT cells in the blood of patients who have had a stem cell transplant. These cells may help predict serious complications like graft-versus-host disease (GvHD) and relapse. Researchers will test 75 adults w…

This study is a registry that will collect medical information and blood samples from 500 adults with myelodysplastic syndromes (MDS) and related conditions. The goal is to learn more about how these diseases develop and progress over time. Participants will not receive any exper…

This early study tests whether a single injection of motixafortide can help reveal tiny amounts of leukemia cells that remain after initial chemotherapy in people with acute myeloid leukemia (AML). Ten adults who have completed 1-2 cycles of treatment will receive the drug and th…

This study is testing a mobile app called my.naviGATE for teens and young adults (ages 15-24) who have finished cancer treatment. The app provides personalized education, peer support, and tracks how patients are doing. Researchers want to see if the app helps patients feel more …

This study will follow 5,000 adults with immune system problems to see if certain blood cell mutations (called clonal hematopoiesis) are linked to their condition. Researchers will track new cases of immune-related diseases over time. No treatments or drugs are tested—this is pur…

This study will create a structured follow-up program for 400 children and young adults who have survived blood cancers like leukemia and lymphoma. Researchers want to better track and understand long-term health problems that can appear years after treatment. The goal is to impr…

This study looks at blood cancer patients who carry drug-resistant bacteria in their gut. Researchers want to find out who is most likely to get a serious infection from these bacteria. They will collect rectal swabs and track patients for 90 days to build a prediction tool. The …

This study looks at how the antibiotic delafloxacin spreads through the body in 20 adults with serious skin, soft tissue, bone, or joint infections. Researchers will measure drug levels in blood and in tissues collected during surgery. The goal is to understand if the drug reache…

This study will follow 75 people with chronic myeloid leukemia who are taking tyrosine kinase inhibitors (imatinib or nilotinib). Researchers want to see if these drugs change blood sugar (HbA1c) and cholesterol levels. The goal is to understand side effects better, not to test a…

This study tests a decision support system called SmaRTWork to help people on sick leave due to muscle or back pain return to work. About 298 adults in Norway will either use the system or receive usual care. The main goal is to see if the tool helps them return to work sustainab…

This study will follow 80 adults with newly diagnosed acute myeloid leukemia (AML) who are receiving intensive chemotherapy. The goal is to measure changes in blood clotting profiles before and after treatment. Researchers hope to better understand bleeding risks and improve care…

This study looks at why people with polycythemia vera (PV), a rare blood disorder that makes too many red blood cells, often struggle with exercise. Researchers will measure blood thickness and oxygen levels in 54 patients during a treadmill stress test. The goal is to see if a b…

This study will compare 100 people with either multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD) to find better ways to tell them apart. Researchers will measure specific proteins in the blood and look at MRI scans. The goal is to improve diagnosis and man…

This observational study will measure how well the body breaks down blood clots in 150 cancer patients (with blood cancers or solid tumors) who also have clotting issues. Researchers will take extra blood samples during routine care to look for markers that might predict bleeding…

This study follows up to 49 people with relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who previously received ARD103 CAR-T cell therapy in an earlier trial. Researchers will track side effects, overall survival, and how long any response lasts. The goal …

This study will collect detailed information from 2000 people with osteomyelitis (a serious bone infection) to help doctors learn which treatments work best. Participants will be followed for at least 8 weeks after treatment to check if the infection is gone. The goal is to creat…

This study will observe 93 adults with myelofibrosis who are taking momelotinib as part of their normal care. Researchers will track how well the drug reduces spleen size after 6 months, providing real-world evidence of its effectiveness.

This study will check how certain leukemia drugs (called tyrosine kinase inhibitors) affect the thyroid gland in people with chronic myeloid leukemia. Researchers will measure thyroid hormone levels in 76 newly diagnosed adults over time. The goal is to learn how often thyroid pr…

This study will follow 100 adults with diabetes and foot ulcers to see how non-vascular factors like nerve damage, infection, and poor blood sugar control affect ulcer severity and healing. Researchers hope to find which risk factors can be changed to prevent ulcers from coming b…

This study will gather and combine medical and genetic data from 2,000 children with acute myeloid leukemia (AML) across France. The goal is to find hidden patterns that predict which patients are most likely to relapse. By creating a large, shared database, researchers hope to i…